000 01269 a2200349 4500
005 20250518072536.0
264 0 _c20210728
008 202107s 0 0 eng d
022 _a1365-2125
024 7 _a10.1111/bcp.14185
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aWesterdijk, Kim
245 0 0 _aImatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
_h[electronic resource]
260 _bBritish journal of clinical pharmacology
_c02 2020
300 _a258-273 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAntineoplastic Agents
_xadverse effects
650 0 4 _aDrug Monitoring
650 0 4 _aHumans
650 0 4 _aImatinib Mesylate
650 0 4 _aIndazoles
650 0 4 _aProtein Kinase Inhibitors
_xadverse effects
650 0 4 _aPyrimidines
650 0 4 _aSulfonamides
650 0 4 _aSunitinib
700 1 _aDesar, Ingrid M E
700 1 _aSteeghs, Neeltje
700 1 _avan der Graaf, Winette T A
700 1 _avan Erp, Nielka P
773 0 _tBritish journal of clinical pharmacology
_gvol. 86
_gno. 2
_gp. 258-273
856 4 0 _uhttps://doi.org/10.1111/bcp.14185
_zAvailable from publisher's website
999 _c30366747
_d30366747